Durlax Top (DURLAX)
CyclicalScore breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹77.6 |
| Market Cap | ₹140.23 Cr |
| P/E Ratio | 19.18 |
| ROCE | 14.76% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | -6.47% |
| Debt/Equity | — |
| Sales Growth | 14.74% |
| Promoter Holding | 51.45% |
| 52-Week Range | ₹30.55 — ₹77.6 |
| Sector | Consumer Durables |
Strengths
- Sales growth of 14.74% shows demand for the company's products is expanding.
- ROCE of 14.76% indicates reasonable capital efficiency in generating operating returns.
- Promoter holding of 51.45% aligns management interests with shareholders.
- Latest quarterly sales of ₹68 crore demonstrate a solid revenue base for a small-cap company.
Concerns
- Net profit declined 6.47% even as sales grew, indicating severe margin pressure or rising costs.
- P/E of 19.18 on declining earnings leaves no margin of safety for a small, cyclical business.
- Piotroski F-score of 4/9 suggests weak financial health and potential operational deterioration.
- Zero dividend yield means investors get no cash return while facing earnings volatility.
AI Analysis
At ₹51, Durlax Top's market cap is ₹140 crore, and I'm being asked to pay 19.18 times earnings. For that price, I expect a business with a clear moat and predictable profits. Instead, I see sales growing 14.74%, but net profit falling 6.47%. The latest quarter shows ₹68 crore in sales and only ₹3 crore in net profit—that's a thin margin of roughly 4.4%. This tells me revenue growth is not translating to the bottom line. The ROCE of 14.76% is decent, but without book value or debt-equity data, I cannot judge the balance sheet's safety. That's a red flag for a value investor. The Piotroski F-score of 4 out of 9 reinforces my concern: the financial health is weak. There is no dividend, so I receive no income while waiting for value to appear. Promoter holding at 51.45% is reassuring, but it doesn't create an economic moat. Furniture is a competitive, fragmented industry with no pricing power. The 52-week range of ₹30.55 to ₹72.00 shows this is a volatile small-cap, not a steady compounder. The PEG ratio of 1.30 is flattering because it uses sales growth, but earnings are contracting—so that metric is misleading. Benjamin Graham taught me to buy with a margin of safety. At 19 times earnings with declining profits and incomplete financials, there is no margin of safety. This looks like a cyclical business facing margin pressure, not a franchise I can own for decades. I'll wait for better numbers, a lower price, or clear evidence that profit growth is catching up with sales growth.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer